Intellia Therapeutics, Inc.(NTLA)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
NTLA | 1.64 B | - | -46.20% | 0.00% | -$3.36 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
IMNM | 2.17 B | - | - | 0.00% | -$2.46 | -64.03% | 0.90x | 0.00% | $30.06 | $11.25 |
BCRX | 2.15 B | - | 33.60% | -40.90% | -$1.40 | - | - | 0.00% | $11.22 | $6.00 |
VRDN | 2.07 B | - | 278.70% | 0.00% | -$3.14 | -65.74% | 0.37x | 0.00% | $34.29 | $13.18 |
RARE | 1.47 B | - | 28.10% | -81.73% | -$5.72 | - | - | 0.00% | $39.89 | $12.73 |
Peer Valuation & Performance Analysis
Peer group analysis for Intellia Therapeutics, Inc. (NTLA) compared to its primary competitors (including IMNM, BCRX, VRDN) reveals distinct metrics. NTLA trades at a valuation premium compared to its competitors, with a P/E ratio of -3.5x versus the peer average of -5.5x (representing a -37% premium). This indicates that the market expects superior growth or commands a quality premium for NTLA. In terms of growth, NTLA's revenue growth of -46.2% lags behind the peer average of 113.5%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 0.0% compared to the peer average of -30.7%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• NTLA ranks #0 in P/E ratio, #4 in revenue growth, and #1 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $12.08 | $12.41 | $11.70 | $11.71 | 8,285,800 | -5.34% |
| 2026-10-06 | $12.50 | $13.22 | $12.04 | $12.37 | 7,949,100 | -2.98% |
| 2026-10-05 | $12.35 | $12.88 | $11.85 | $12.75 | 4,962,800 | +4.00% |
| 2026-10-02 | $12.42 | $12.77 | $12.10 | $12.26 | 4,501,800 | +1.16% |
| 2026-10-01 | $11.98 | $12.65 | $11.82 | $12.12 | 7,445,400 | +0.50% |
| 2026-09-30 | $11.96 | $12.23 | $11.75 | $12.06 | 5,314,800 | +0.25% |
| 2026-09-29 | $11.49 | $12.05 | $11.42 | $12.03 | 5,014,100 | +5.34% |
| 2026-09-28 | $11.72 | $11.80 | $11.33 | $11.42 | 3,294,100 | -2.81% |
| 2026-09-25 | $12.33 | $12.33 | $11.66 | $11.75 | 2,975,900 | -3.37% |
| 2026-09-24 | $12.13 | $12.21 | $11.62 | $12.16 | 4,807,600 | -1.38% |
| 2026-09-23 | $12.72 | $12.85 | $11.96 | $12.33 | 5,034,700 | -2.84% |
| 2026-09-22 | $12.27 | $12.97 | $12.14 | $12.69 | 3,920,500 | +3.85% |
| 2026-09-21 | $12.50 | $12.65 | $12.14 | $12.22 | 3,732,000 | +0.66% |
| 2026-09-18 | $12.15 | $12.47 | $11.87 | $12.14 | 8,619,300 | -0.98% |
| 2026-09-17 | $11.99 | $12.87 | $11.95 | $12.26 | 5,753,200 | +6.70% |
Explore More Analysis for NTLA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.